DR. HARRY L MALECH, M.D.
Osteopathic Medicine at Beech Tree Rd, Bethesda, MD

6423311, Jul 23, 2002

Dec 21, 1999

09/468727

Michael Mardiney, III - Baltimore MD
Harry L. Malech - Bethesda MD

The United States of America as represented by the Department of Health and Human Services - Washington DC

A01N 6300

424 937, 435 695, 435325, 435372, 604 20, 514 12

The present invention provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiation, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiation; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiation. The invention also provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiomimetic compound, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiomimetic compound; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiomimetic compound.

6863885, Mar 8, 2005

Jul 22, 2002

10/201212

Michael Mardiney, III - Baltimore MD, US
Harry L. Malech - Bethesda MD, US

The United States of America as represented by the Department of Health and Human Servies - Washington DC

A01N065/00, C12P021/02, C12N005/0008, A61K038/00, A61M005/00

424 937, 435 695, 435325, 435372, 514 12, 604 401, 604 7

The present invention provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiation, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiation; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiation. The invention also provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiomimetic compound, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiomimetic compound; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiomimetic compound.

6103694, Aug 15, 2000

Apr 10, 1998

8/983532

Michael Mardiney - Baltimore MD
Harry L. Malech - Bethesda MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

A61F 204, C12P 2102, A61K 3514

514 12

The present invention provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiation, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiation; and (c) transplanting the donor hematopoietic pluripotent cells into the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiation. The invention also provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiomimetic compound, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiomimetic compound; and (c) transplanting the hematopoietic pluripotent cells into the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiomimetic compound.

6060317, May 9, 2000

Aug 11, 1998

9/133033

Harry L. Malech - Bethesda MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

C12N 1563, C07K 1478, C12M 124

435456

In accordance with the present invention, there are provided methods of transducing cells comprising providing a flexible closed culture container having cells therein and contacting said cells with a viral-vector in the presence of a multi-functional chemical moiety. Also provided are methods of delivering a functional protein to a subject in need thereof, comprising transducing mammalian cells according to the invention method and introducing said cells into a subject in need thereof. Also provided are cell-culture systems for transducing cells, comprising a flexible closed culture container and a multi-functional chemical moiety therein.

5593966, Jan 14, 1997

May 24, 1990

7/527767

Harry L. Malech - Bethesda MD
Daniel Rotrosen - Takoma Park MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

A61K 3800, C07K 700, C07K 706

514 16

Peptide derivatives with inhibitory activity on the enzyme systems involved in the oxidative burst of human phagocytic cells comprise six and seven amino acid peptide sequences from human cytochrome b. sub. 558. The derivatives may be used in medicaments for the treatment of inflammatory diseases.

5585346, Dec 17, 1996

Mar 31, 1989

7/331652

Harry L. Malech - Bethesda MD
Karen J. Lomax - Silver Spring MD
Daniel Rotrosen - Takoma Park MD
Hiroyuki Nunoi - Rockville MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

A61K 3800, C07K 1400, C07K 708, C07K 706

514 12

Peptide derivatives with inhibitory activity on the enzyme systems involved in the oxidative burst of human phagocytic cells comprise a certain sequence of a number of carboxyl-terminal amino acids of human cytochrome b. sub. 558. The derivatives may be used in medicaments for the treatment of inflammatory diseases.